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Abstract
Reliance on evidence-based medicine requires high methodological standards from guideline developers. We sought to determine the
methodological quality of guidelines on pneumonia and urinary tract infections (UTIs). We included guidelines published by national or
international committees in the last 10 years providing recommendations for antibiotic type or duration. We applied the Appraisal of
Guidelines for Research and Evaluation II checklist, adding under each item the speciﬁc focus relevant to bacterial infections, addressing
antibiotic resistance and local epidemiology. Three assessors scored each guideline independently. Mean aggregated scores, converted to
percentage per domain, are presented. We included 13 guidelines on the treatment of pneumonia and seven guidelines for the treatment of
UTI. ‘Scope and purpose’ scored 69.4% for pneumonia and 71.4% for UTI. Guidelines were downgraded for lack of an epidemiological
overview relevant to intended users. ‘Stakeholder involvement’ scored 39.5% for pneumonia and 44.5% UTI, with the major fault being lack
of patient consultation. ‘Rigour of development’ scored 42.8% for pneumonia and 56.9% for UTI. Commonly, the search process lacked
precision, no risk of bias assessment was performed, outcomes in primary studies were not critically assessed or used to direct
recommendations, and there was no formal methodology for formulating recommendations. ‘Clarity of presentation’ scored highest: 67.7%
for pneumonia and 68.5% for UTI. ‘Applicability’ of the guidelines in antibiotic stewardship programmes was usually not addressed: 16.9%
and 25.4%, respectively. ‘Editorial independence’ scored 30.6% for pneumonia and 55.6% for UTI. Formal examination of guidelines in
infectious diseases showed worrying ﬁndings related to core methodology and potential bias caused by competing interests.
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Background
Globalization and the emphasis on evidence-based medicine
have resulted in increasing uniformity between centres
worldwide in patient management. This implies increasing
reliance on evidence-based guidelines and expert consensus
statements rather than basing practice on local habits or
opinion. Recommendations in infectious diseases, now more
than ever, have a huge impact on patient management and local
policy. This, in turn, may affect local epidemiology.
The responsibility of guidelines developers is therefore to
adequately summarize and make use of the available evidence.
This includes systematic methods for literature searches,
deﬁned criteria for selecting studies, a priori deﬁnition of the
meaningful outcomes to be extracted from the available
literature, critical appraisal of the risk of bias, and ranking of
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the recommendations by evidence grading. A clear require-
ment is that the guideline developers be free of conﬂicts of
interests or that these be carefully addressed when they are
voting on the ﬁnal recommendations. These and other
methodological requirements from guideline developers have
been formally devised and published. However, in infectious
diseases, especially with bacterial infections, there are further
considerations for guideline development, in addition to the
standard criteria relevant to all guidelines in medicine. These
pertain to antibiotic resistance. First, the evidence for antibi-
otic treatment cannot be taken directly from clinical trials, but
must be placed in the context of time and location as regards
pathogen distribution and antibiotic resistance. Second, the
guidelines should consider the ecological impact of treatment
recommendations by locale; recommending third-generation
cephalosporins universally for hospitalized community-
acquired pneumonia (CAP) might lead to the emergence of
extended-spectrum b-lactamases in locations where these are
rare. The ﬁnal recommendations should be ﬂexible enough to
accommodate different settings worldwide, or otherwise
specify the conditions to which the guidelines apply.
Further speciﬁc problems in guideline development for
bacterial infections include the paucity of evidence. Evidence is
often lacking for critically ill patients, who are seldom included
in clinical trials. Thus, the patient population included in
randomized controlled trials (RCTs) on bacterial infections
might not represent the patient population seen in clinical
practice [1]. Conceptual trials examining questions such as
‘Should we treat this infection? How long should we treat this
infection? Should patients be hospitalized?’ are rare or
non-existent. Trials are usually designed to assess the effects
of a speciﬁc antibiotic for a speciﬁc infection, usually to obtain
drug approval. In trials, antibiotics are frequently tested for
indications that do not reﬂect the drugs’ use in clinical practice
(e.g. levoﬂoxacin and doripenem for urinary tract infection
(UTI), and ertapenem for CAP). Guidelines developers must
use the evidence judiciously to avoid recommendations
indirectly led by the industry (e.g. levoﬂoxacin for UTI), and
use knowledge and understanding about antibiotics’ spectrum
of activity, pharmacokinetics and pharmacodynamics to apply
clinical trial results to recommended practice.
We sought to determine the methodological quality and
reliability of guidelines on bacterial infections, focusing on
pneumonia and UTI. We systematically reviewed national and
international guidelines on antibiotic treatment of pneumonia
and UTI published in the last 10 years. We used the Appraisal
of Guidelines for Research and Evaluation II (AGREE-II)
criteria to appraise guidelines quality [2], incorporating ques-
tions related to bacterial infections within the AGREE-II
domains.
Methods
We included guidelines published by national or international
committees, organizations or societies on the management of
pneumonia and UTI in adults. Within the guidelines, we
focused on the recommendations for antibiotic treatment
(type and duration). Pneumonia included CAP, hospi-
tal-acquired pneumonia, and ventilator-associated pneumonia.
UTI included cystitis, pyelonephritis, other complicated UTIs
and catheter-associated UTIs in men and women. When more
than one version of the guidelines was available, we used the
most detailed version (even if available only online). We
limited inclusion to guidelines published in English, in the last
10 years (2004–2013).
We searched PubMed, Google, guideline databases, includ-
ing NICE (http://guidance.nice.org.uk/CG/Published) and the
Scottish Intercollegiate Guidelines Network (SIGN) (http://
www.sign.ac.uk/guidelines/index.html), and the websites of
professional societies, including the European Society of
Clinical Microbiology and Infectious Diseases, the Infectious
Diseases Society of America (IDSA), and national thoracic and
urological associations. We used the terms ‘guidelines’,
‘recommendations’ or ‘consensus’ crossed with ‘pneumonia’
and ‘urinary tract infection’.
We applied the AGREE-II checklist [3] to each of the
guidelines, adding under each item the speciﬁc focus relevant
to bacterial infections. The checklist comprises 23 items,
addressing six domains. Each of the 23 items receives a score
between 1 (strongly disagree) to 7 (strongly agree), and the
scores of each domain are summarized to give a domain quality
score. We did not estimate overall assessment scores. The
AGREE-II deﬁnitions and the focus with regard to bacterial
infections for each item are shown in Table S1. The data
pertinent to bacterial infections per domain included the
following:
1. Scope and purpose: review of the epidemiology of the disease
in the locale targeted by the guidelines. Under ‘health
question(s) covered by the guideline’, we looked for deﬁni-
tions of the outcomes of the infection relevant to patients,
using outcome trees or other methods. Under the deﬁnitions
of the target population, we checked whether age, place of
infection acquisition, immunocompromised status and infec-
tion severity were addressed, in addition to patient charac-
teristics speciﬁc to the types of infections (chronic lung
diseases for community-acquired pneumonia; time in hospital
for hospital-acquired pneumonia/ventilator-associated pneu-
monia; sex, catheter and diabetes for UTI).
2. Stakeholder involvement: inclusion of experts from relevant
ﬁelds in the guideline development group, including
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infectious diseases, infection control, microbiology, phar-
macology, general practice, geriatrics, intensive care, and
acute care, and the relevant society (thoracic societies
for pneumonia, and urological/gynaecological societies for
UTI); involvement of patients and the public in designing the
scope and purpose of the guidelines.
3. Rigour of development: under the item of ‘criteria for
selecting the evidence’, we checked whether inclusion
criteria addressed bacterial epidemiology and antibiotic
resistance. Under the item of ‘strengths and limitations of
the body of evidence’, we put an emphasis on the
AGREE-II-deﬁned criterion of ‘appropriateness/relevance
of primary and secondary outcomes’. The guidelines
should have addressed the effect of different antibiotic
choices on the outcome(s) of relevance, as identiﬁed
under ‘scope and purpose’. Under the item ‘health
beneﬁts, side effects, and risks’, we checked whether
guidelines addressed the ecological impact of the antibiotic
recommendations.
4. Clarity of presentation: we checked whether antibiotic
treatment recommendations were stratiﬁed at least by
place of infection acquisition, age and infection severity; and
whether the recommendations addressed the epidemio-
logical settings for which the recommendations are rele-
vant, or recommendations were stratiﬁed by
epidemiological setting. Under ‘different options for man-
agement of the condition or health issue are clearly
presented’, we checked whether alternatives that have
not been tested in RCTs, with a similar spectrum of
coverage and activity, were addressed.
5. Applicability: we examined whether the guidelines
addressed antibiotic stewardship programmes and how to
implement recommendations within such programmes;
provided directions for antibiotic audits; and addressed
performance measures relevant to the guidelines.
6. Editorial independence: as deﬁned by AGREE-II.
Before the rating process was begun, the contents of each
item of the AGREE-II checklist were discussed (Table S1),
scoring was piloted by three assessors, and differences were
discussed. The three assessors then applied the checklist to
each guideline independently, detailing the reasons for the
scoring of each item (available from the authors on request).
Large differences (>4 points) between assessors were dis-
cussed, and omissions or errors were corrected, although no
attempt was made to reach a consensus. The ﬁnal scores of
the three reviewers were aggregated and converted to a
percentage for each domain, as recommended [4]. The
correlation of the scores between pairs of assessors was
examined by use of Spearman’s correlation coefﬁcient.
Pooled mean/median scores for all guidelines in each
category (pneumonia and UTI) were calculated for each
domain.
Results
Our search resulted in 2053 references, among which 42
potentially relevant guidelines for pneumonia or UTI treatment
issued by formal national or international associations were
identiﬁed. Twenty-two were excluded because of overlap with
another included guideline or non-English language, and 13
guidelines on the treatment of pneumonia [5–17] and seven
guidelines for the treatment of UTI [18–24] were included.
The guidelines were published between 2004 and 2013, and
spanned all the subtypes of infection under each diagnosis. The
guidelines originated from Europe, the USA, Asia, Brazil, South
Africa, Japan, and the Gulf Cooperation Council. The corre-
lations of the scores between the three pairs of assessors for
all items and all guidelines were 0.828, 0.815, and 0.746
(p <0.001), indicating high correlation. Aggregated results of
the AGREE-II scores and pooled results of all guidelines are
provided in Tables 1 and 2. Detailed scores per guideline are
provided in Tables S2 and S3. The top-ranking antibiotic
recommendations per guidelines are shown in Tables S4
and S5.
Scope and purpose
This item is concerned with ‘the overall aim of the guideline,
the speciﬁc health questions, and the target population’. The
means of the aggregated scores were 69.4% (median, 72.2%;
range, 48.2–87%) for pneumonia, and 71.4% (median, 74.1%;
range, 33.3–87%) for UTI.
Although the objectives of the guidelines (item 1) were
generally described, nearly all guidelines were downgraded
for lack of statements on the expected health beneﬁts or
impact of the guidelines on society, populations of patients,
or individuals. As many of the guidelines were updates of
previous versions, we searched for some assessment of the
impact of the previous version of the guidelines, but did not
ﬁnd such assessments. Under description of the health
question (item 2), eight of 13 guidelines on pneumonia and
only two of seven guidelines on UTI deﬁned and described
the outcomes relevant to the infection. Most guidelines
presented an epidemiological overview of the causative
bacteria and their resistance proﬁles in general, but not all
reviewed data speciﬁcally relevant to the settings targeted by
the guidelines. Of the pneumonia guidelines, six of 13
guidelines addressed the epidemiology relevant to the
targeted users; of the UTI guidelines, two of seven provided
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locally relevant bacteriological data. Population description
(item 3) scores were downgraded mainly for lack of deﬁni-
tions of patient subgroups relevant to the studied infection in
advance.
Stakeholder involvement
This item focuses on ‘the extent to which the guideline was
developed by the appropriate stakeholders and represents the
views of its intended users’. The means of the aggregated
scores were very low, at 39.5% (median, 38.9%; range, 0–
70.4%) for pneumonia, and 44.5% (median, 37%; range, 5.6–
100%) for UTI.
The scores were low for all three items included under this
domain. The composition of the guideline development group
or authorship team (item 4) received the highest score of the
three, but was poorly adapted to the topic or poorly described
in most guidelines. The guideline panel of the high-scored
guidelines [6,11,13,14,18–20,22] represented experts from
microbiology, infectious diseases, pharmacology, medical and
intensive care, general practice, geriatrics, and public health,
and the relevant specialists (pulmonology, thoracic diseases,
urology, and gynaecology). Of the authors listed in UTI
guidelines, 29% were women (45% in the SIGN guidelines [19]
and 24% in all others). The lowest score was given to seeking
the views and preferences of the target population (item 5).
All but three guidelines were scored 1 by all assessors
(strongly disagree). Two guidelines [11, 19] were subjected to
public consultation before publication, and the IDSA guidelines
for CAP [15] addressed consumer preference, but only for
quality indicators. However, none of the guidelines described a
process of explicit patient consultation. The target users of the
guidelines (item 6) were generally not speciﬁcally described,
but all assessors felt that this item is probably less relevant to
our topic, as target users are deﬁned by the scope of the
guidelines.
Rigour of development
This domain relates to ‘the process used to gather and
synthesize the evidence, and the methods used to formulate
the recommendations and to update them’ It is a large domain,
including eight items, and is the core of the guideline
methodology. The mean scores were 42.8% (median, 39.6%;
range, 18.8–66.7%) for pneumonia, and 56.9% (median, 58.3%;
range, 23.6–89.6%) for UTI.
The search process (items 7 and 8) scored low both for
pneumonia and for UTI. No search strategy was provided or
referred to in seven of 13 guidelines for pneumonia and three
of eight guidelines for UTI (item 7). Otherwise, scoring points
TABLE 1. Appraisal of Guidelines for Research and Evaluation II scoring of guidelines for the treatment of pneumonia
Issuing society
Year of
publication
Topic(s)
addressed
by the
guidelines
Scope and
purpose (%)
Stakeholder
involvement
(%)
Rigour of
development
(%)
Clarity of
presentation
(%)
Applicability
(%)
Editorial
independence
(%)
Swedish Society of Infectious
Diseases [5]
2012 CAP 53.7 20.4 36.8 75.9 1.4 94.4
Dutch Working Party on
Antibiotic Policy/Dutch
Association of Chest
Physicians [6]
2012 CAP 79.6 44.4 65.3 92.6 25 25.0
European Society of Clinical
Microbiology and Infectious
Diseases/European Respiratory
Society [7]
2011 LRTI 63.0 51.9 50 70.4 0.0 25.0
Spanish Society of Pulmonology
and Thoracic Surgery [8]
2010 CAP 64.8 0.0 20.8 55.6 1.4 0.0
British Thoracic Society [14] 2009 CAP 83.3 66.7 80.6 96.3 48.6 44.4
Brazilian Thoracic Association [9] 2009 CAP 46.3 7.4 25.7 38.9 2.8 44.4
American Burn Association [10] 2009 VAP 72.2 38.9 39.6 33.3 2.8 0.0
British Society of Antimicrobial
Chemotherapy [11]
2008 HAP 74.1 55.6 66.7 66.7 13.9 36.1
South African Thoracic Society
[12]
2007 CAP 83.3 25.9 23.6 57.4 4.2 0.0
Gulf Cooperation Councila [13] 2007 CAP 66.7 70.4 31.9 74.1 37.5 0.0
Infectious Diseases Society of
America/American Thoracic
Society [15]
2007 CAP 87.0 68.5 54.9 92.6 43.1 58.3
Infectious Diseases Society of
America/American Thoracic
Society [16]
2005 HAP/VAP/HCAP 87.0 35.2 41.6 81.5 36.1 69.4
Japanese Respiratory Societyb [17] 2004 HCAP 48.2 27.8 18.8 44.4 2.8 0.0
Average 69.4 39.5 42.8 67.7 16.9 30.6
SD 14.3 22.9 19.6 20.8 18.5 30.96
Median 72.2 38.9 39.6 70.4 4.2 25.0
CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; LRTI, lower respiratory tract infection; SD, standard
deviation; VAP, ventilator-associated pneumonia.
aCooperative framework of six countries including the United Arab Emirates, the Kingdom of Bahrain, the Kingdom of Saudi Arabia, the Sultanate of Oman, the State of Qatar, and
the State of Kuwait.
bThe Japanese Respiratory Society guidelines were published in several papers that were included in the review. The full reference list is shown in Tables S1–S5.
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were deducted for a restricted (only PubMed), non-structured
search. Interventions were not included in the search strat-
egies of all guidelines. The criteria for selecting the evidence
(item 8) were scored even lower than the methods of the
search, as these were not usually deﬁned. When they were
deﬁned, the selection criteria did not include epidemiological
considerations that would result in a set of studies relevant
with regard to bacterial distribution and antibiotic resistance.
An intention to critically appraise the evidence (item 9), as
reﬂected by using a grading table, was present in all but two
guidelines for pneumonia. However, evidence grading was
limited to the classiﬁcation of studies by design. None of the
guidelines performed a risk of bias assessment of individual
trials, addressing selection, performance, detection, attrition,
reporting or other biases, except for the SIGN guidelines for
UTI [19]. None of the guidelines used the GRADE method-
ology. More importantly, in our view, was that almost none of
the guidelines included an assessment of the relevance of the
outcomes of individual studies, or a statement on the appro-
priateness of the antibiotics compared. The IDSA/American
Thoracic Society guidelines on CAP were an exception with
regard to outcome deﬁnition [15], deﬁning mortality as the
relevant outcome, and selecting studies for inclusion by using
this outcome. The methods for formulating the recommenda-
tions (item 10) were scored very low for both pneumonia and
UTI guidelines, as almost none of the guidelines described a
formal process of voting or other techniques to reach a
consensus on speciﬁc recommendations. A few guidelines
described an informal process of meetings, emails, review of
drafts, and discussions, and received an intermediate score.
High scores were given to single guidelines using Delphi
methods to combine expert opinions, a voting process to
deﬁne recommendations, or the ‘SIGN’ methodology, which is
a formal process based on grading scores [14,15,19].
Considering the health beneﬁts, side effects and risks in
formulating the recommendations (item 11) received a
medium score for both pneumonia and UTI. Surprisingly, in
guidelines, there was usually a dissociation between outcomes
and recommendations for treatment. The reasoning provided
for antibiotic selection was their expected spectra of coverage.
Clinical trials were sometimes (infrequently) quoted in favour
of speciﬁc recommendations, but the outcomes assessed in the
trials and on which the guideline developers based their
recommendations were not discussed. Similarly, the ecological
implications of the different antibiotics were not explicitly
discussed. Often, guidelines provided a list of antibiotic options
for a certain type of infection, mainly for hospital-acquired
infections, as appropriate. Although, as previously noted, most
guidelines deﬁned an evidence grading score, surprisingly, in
approximately half of the guidelines, the ﬁnal recommenda-T
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tions were not linked to an evidence grade (item 12, explicit
linking between the recommendations and the supporting
evidence). Similarly, approximately half of all guidelines did not
provide references to primary studies that support the
recommendations.
External review of the guidelines (item 13) was speciﬁcally
reported in few guidelines: three of 13 for pneumonia, and four
of seven for UTI. Naturally, guidelines published in peer-re-
viewed journals were reviewed; however, a true external
review should be part of the guideline development process
prior to submission of the ﬁnal version for publication. Finally,
in this domain, only a few guidelines (two for pneumonia and
two for UTI) noted a plan for future updates. We gave a low,
but not minimal, score to guidelines that were updates of
previous versions.
Clarity of presentation
This domain deals with ‘the language, structure and format of
the guideline’. Relative to other domains, this domain scored
high overall, with a mean of 67.7% (median, 70.4%; range, 33.3–
96.3%) for pneumonia, and a mean of 68.5% (median, 61.1%;
range, 48.2–94.4%) for UTI.
Clarity and avoiding ambiguity (item 15) was scored high in
most guidelines. Guidelines usually stratiﬁed recommenda-
tions by clinically relevant subgroups. The highest scores were
given to guidelines that also addressed the epidemiological
settings for which the recommendations are relevant. Guide-
lines for hospital-acquired infections did not always refer to
speciﬁc antibiotics. However, all assessors considered state-
ments such as ‘antibiotic choice should be directed by the
local epidemiology’ as appropriate, provided that some
directives were given on how to use local epidemiology and
on duration of treatment. Within this domain, the lowest
scores were given to item 16: ‘clear presentation of the
different options for management of the condition or health
issue’. Guidelines were downgraded when they provided a list
of antibiotic options with no grading, ranking or explanation
of how to choose between the options. Most did not
consider alternatives to antibiotics tested in RCTs. Finally,
high scores were given to most guidelines for item 17: ‘key
recommendations are easily identiﬁable’. Recommendations
were usually presented in tables, ﬁgures, or summary
statements.
Applicability
The applicability domain pertains to ‘the likely barriers and
facilitators to implementation, strategies to improve uptake,
and resource implications of applying the guideline’. This
domain received a very low score, as most guidelines did not
address these items: a mean of 16.9% (median, 4.2%; range, 0–
48.6%) for pneumonia, and a mean of 25.4% (median, 29.2%;
range, 0–68.1%) for UTI.
None of the guidelines analysed facilitators of and barriers
to guideline application (item 18). The higher-scored guide-
lines provided some advice or tools for putting the recom-
mendations into practice (item 19). These were in the form of
recommendations on how to adapt the guidelines locally, who
should undertake implementation and dissemination, recom-
mendations for implementation, and dissemination strategies
[13,19]. Monitoring and/or auditing criteria (item 21) were
well described in few guidelines, which proposed performance
measures [6,15] or a formal audit tool [14] for CAP, and
auditing measures for UTI [19]. The American Congress of
Obstetricians and Gynecologists guidelines for UTI suggested a
single performance measure: the percentage of women with
pyelonephritis treated for 14 days [23]. This guideline was
scored low, as the evidence backing this measure was lacking.
Nearly none of the guidelines considered the potential
resource implications of applying the recommendations
(item 20): ten of 13 guidelines for pneumonia and ﬁve of
seven guidelines for UTI were given the minimal score by all
three assessors.
Editorial independence
This domain is concerned with processes and appropriate
statements ensuring that the formulation of recommendations
was not unduly biased by competing interests. The scores
were low, with a mean of 30.6% (median, 25%; range, 0–94.4%)
for pneumonia, and a mean of 55.6% (median, 66.7%; range, 0–
94.4%) for UTI.
The higher-scored guidelines explicitly reported funding
(item 22) by a non-proﬁt organization, referred to the funding
of all stages of guideline development and meetings of the
authors, and declared no conﬂicts of interests (item 23) for all
authors. The guidelines detailing all conﬂicts of interests of the
authors never provided an explanation of how these were
dealt with (e.g. exclusion of the author when voting on an
intervention with a possible conﬂict of interest). These
guidelines were given an intermediate score.
Discussion
Guidelines on the treatment of pneumonia and UTI scored
reasonably well with respect to scope and purpose deﬁnitions
and the clarity of presentation of the ﬁnal recommendations.
All other domains were scored dismally low, with a pooled
score below 50% for all domains in pneumonia and most
domains in UTI. These domains refer to the core methodology
of the guideline’s development process, the quality of the
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actual recommendations, patient involvement, guideline imple-
mentation, and conﬂicts of interests. Guidelines published by
professional guideline development groups, most prominently
the SIGN guidelines, scored highest on methodology. How-
ever, they scored low for parameters speciﬁcally relevant to
bacterial infections, such epidemiology and ecological consid-
erations. Guidelines developed by societies of infection and
microbiology scored low on methodology, and, surprisingly,
most also scored low for the epidemiological considerations.
Formal examination of the guidelines with the AGREE-II
score revealed two important limitations of current guidelines
in infectious diseases: interventions and outcomes. First, the
interventions (i.e. antibiotic considered to be relevant for the
infection) were not deﬁned in advance (no deﬁnition, and no
structured search strategy). When the evidence was reviewed,
there was no critical appraisal of the relevance of the antibiotics
identiﬁed. Guidelines should start with clinical questions:
population, well-deﬁned interventions, and main outcomes of
interest. A natural process would be to deﬁne in advance the
antibiotics considered to be relevant for the infection and
search for these. Given the common coverage and mechanism
of action of different antibiotics, one could consider deﬁning in
advance antibiotics that will be used as indirect evidence for the
efﬁcacy of another antibiotic, e.g. inferring on the efﬁcacy of
ciproﬂoxacin from trials assessing levoﬂoxacin. With such a
process, trials of ertapenem for CAP would probably not be
included a priori. The strategy used by most current guidelines
is to sum up phase 3/4 non-inferiority trials conducted as part
of the drug approval process, with little criticism on the
relevance of the antibiotics compared.
Second, outcomes were usually not deﬁned in advance, the
relevance of the outcomes examined in the primary studies
were not discussed, and, most interestingly, the relationships
between actual recommendations and outcomes in primary
studies were rarely described. None of the guidelines
addressed the outcomes targeted when giving recommenda-
tions for antibiotic treatment. The guidelines addressed the
coverage obtained with the different antibiotic choices, but
almost none addressed clinical outcomes in the antibiotic
recommendation section (i.e. why is it important to achieve
adequate coverage and what we want to achieve by treating
patients; an exception was noted for the IDSA/ESCMID
guidelines for cystitis [20]). The patient perspective was never
addressed. The result is dissociation between what we expect
from antibiotic treatment in clinical practice and the recom-
mendations.
A structured search and risk of bias assessment is routine in
systematic reviews. Risk of bias assessment is incorporated in
the evidence-grading methods using GRADE methodology
[25]. Guidelines have advanced in the last decade from
non-evidence-based expert opinion to a semi-systematic
process with grading of evidence by study design. However,
there is a still large gap between this and a truly systematic
process. Currently, the methods for evidence grading in all of
the guidelines that we identiﬁed were developed internally,
were variable, were non-comparable, and were based only on
study design. Most grading tables had important limitations.
For example, the IDSA evidence-grading system does not
address systematic reviews, and, consequently, systematic
reviews are conspicuously missing from the evidence review in
most recommendations. The AGREE-II and PRISMA state-
ments [3,26] recommend that the search strategy and
selection criteria address population, interventions, compari-
sons, and outcomes (PICO). None of the available guidelines
formulated such a strategy. Admittedly, all guidelines had a
broader scope than treatment alone, and broad searches of
the ﬁeld were therefore conducted. However, multiple search
strategies should optimally be designed for each of the
questions addressed by the guidelines. The search strategy
for antibiotic treatment should address the four PICO
components. The overall systematic process should ensure
recommendations using reasonable antibiotics and relying on
patient-relevant outcomes.
We searched for epidemiological and ecological consider-
ations in the formulation of the guidelines. We found
inconsistent matching of antibiotic treatment recommenda-
tions to local bacterial distribution and antibiotic resistance.
The ecological considerations of selecting one or another
antibiotic from a list of options, in different epidemiological
settings, were rarely discussed. This is important to ensure
adequate coverage of the recommended antibiotics, but also
to avoid recommending antibiotics that are too broad-spec-
trum for locations with low baseline resistance. A study
examining the predicted changes in antibiotic use in The
Netherlands estimated that there would be a large increase in
antibiotic use if the IDSA guidelines for CAP were to be
implemented there, with potential important ecological con-
sequences [27].
Patient consultation is relevant for any disease. For UTI,
especially uncomplicated UTI among young women, consulting
healthy women and patients is particularly relevant to direct
management. Studies have shown that women frequently agree
to defer antibiotic treatment, and in most of them symptoms
resolve spontaneously [28, 29]. We did not identify an explicit
process of patient consultation in all guidelines.
A very low score was given to the methods for formulating
the recommendations and the domain of editorial indepen-
dence. A formal process to decide on the ﬁnal recommenda-
tions is important to limit inappropriate inﬂuences. Conﬂicts of
interests are common and almost unavoidable in guideline
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panels. Not only should conﬂicts of interests be reported, but
it is very important that users of guidelines be aware of how
conﬂicts were dealt with (e.g. exclusion of a person with a
conﬂict from contributing to a speciﬁc recommendation).
Finally, recommendations for treatment will only have an effect
if effectively implemented. Antibiotic stewardship and guideline
application is a major issue in infectious disease. Existing
guidelines rarely addressed the implementation of recommen-
dations within antibiotic stewardship programmes.
Our analysis is limited by the use of a panel of assessors
who were all from the ﬁeld of infectious diseases and who
were not blinded to the source of the guidelines. We excluded
guidelines that were not published in English, as we targeted
guidelines that might be read and used worldwide. It is possible
that guidelines published in local languages perform better with
respect to consideration of local epidemiology. We did not
estimate overall assessment scores, also recommended by
AGREE-II. We opted for the more objective and deﬁned
scoring of individual items. Our ﬁnal scores were lower than
those reported in a systematic review examining AGREE-II
scores for WHO guidelines after the establishment of a
Guidelines Review Committee [30]. These guidelines
addressed treatment, prevention and diagnosis in the ﬁelds
of human immunodeﬁciency virus, tuberculosis, malaria, inﬂu-
enza, and hand hygiene. Our scores might have been lowered
by the addition of content relevant to bacterial infections to
the score items. We are not aware of other evaluations of
guidelines on bacterial infections using the AGREE-II score.
In conclusion, we found wide room for improvement in
guidelines on pneumonia and UTI. Speciﬁcally, systematic
methods for formulating the questions addressed by the
guidelines should result in better selection of antibiotics
targeting patient-relevant outcomes. A unique feature of
guidelines in infectious diseases is the need to address local
epidemiology.
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